A US FDA advisory committee's strong backing of Spark Therapeutics Inc.'s Luxturna (voretigene neparvovec) for inherited retinal dystrophy at an Oct. 12 meeting came with an endorsement of the sponsor's novel endpoint for assessing the gene therapy's impact on functional vision.
The Cellular, Tissue and Gene Therapies Advisory Committee unanimously concluded that voretigene (AAV2-hRPE65v2) had a favorable risk/benefit profile in patients...





